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R1003A widely acclaimed debut book, 
published this year, has won the 
prestigious Wellcome Trust book prize, 
announced last month. The book tells 
the story of a poor southern tobacco 
farm worker whose cancer cells, taken 
without her or her family’s knowledge, 
became one of the most important 
tools in cell biology and medicine.
When Henrietta Lacks was dying from 
cervical cancer in a Baltimore hospital 
in 1951, little did she know that she 
would one day become one of the most 
important women in medicine. After her 
death, scientists removed cells from her 
body and grew them in the laboratory.
Over the following decades, 
more than 50 million tonnes of 
her cells were replicated. HeLa 
cells, as they became known, have 
helped to develop polio vaccines, 
in vitro fertilisation techniques, 
genetics research and aided the 
understanding of cancers along with 
the manufacture of drugs for herpes 
and influenza. Their use has been 
acknowledged in more than 60,000 
research papers.
But this contribution is not 
without controversy. Despite Lacks’ 
widespread influence, her family 
continue to live in poverty. The 
extraordinary tale has been recounted 
in The Immortal Life of Henrietta 
Lacks, the best-selling story of Lacks’ 
life and death written by the science 
writer Rebecca Skloot, published in 
the US in February and released in 
Britain in the summer, to widespread 
acclaim.
“It’s wonderful that the prize has 
been awarded to a book that was 
such a labour of love for its author,” 
said Clare Matterson, director of 
medical humanities at the Wellcome 
Trust. Rebecca Skloot spent a great 
deal of time with Lacks’ family. If 
science exploited Lacks, Skloot 
was certainly keen not to. She was 
determined that Lacks would be 
Henrietta as well as HeLa.
The Immortal life of Henrietta Lacks 
has been described as a ‘biomedical 
thriller’ and chronicles the tale of 
how the 31-year-old’s cancer cells 
were removed from her body without 
her family’s permission. It charts 
the tribulations of her impoverished 
relatives, and the author’s obsession 
with the mystery of how such an 
influential figure ended up being 
buried in an unmarked grave just 
outside Roanoke, the small town in 
Virginia where she grew up.
Lacks was only confirmed as the 
source of the cells in 1973, to the 
surprise of her relatives. In 2001, HeLa 
cells were trading at $167 a vial. Her 
descendants have never received any 
money from their ancestor’s  
gift to science.
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Success: Rebecca Skloot’s account of the life of Henrietta Lacks has won the Wellcome Trust 
science book prize. (Picture: Obstetrics & Gynaecology/Science Photo Library.)
“This cell line is used all around the 
world and revolutionised cell biology 
because they grew so well in culture, 
said William Earnshaw, principal 
research fellow at the University of 
Edinburgh’s Centre for Cell Biology. 
“They yielded a huge amount of 
information,” he said.
While their research value is 
unquestioned, the tumour cells had 
created havoc in Henrietta Lacks’ body. 
Skloot recounts the lab technician 
Mary Kubicek who was present at the 
autopsy. “The tumours had completely 
blocked her urethra, leaving doctors 
unable to pass a catheter into her 
bladder to empty it. Tumours the size 
of baseballs had nearly replaced her 
kidneys, bladder, ovaries and uterus. 
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in small white tumours it looked as if 
someone had filled her with pearls.”
It was perhaps the ferocity of 
her cancer that made the cells 
grow successfully in the laboratory. 
“Henrietta’s cells weren’t merely 
surviving, they were growing with 
mythological intensity,” writes Skloot.  
“Soon they were being shipped to 
research institutes around the world, 
where they enabled scientists to 
perform experiments that would have 
been impossible on a living human,” 
she writes.
The story’s relevance to black 
society has also made the book 
particularly appealing to parts of the 
US public. Lacks’ story has been 
portrayed as an example of the 
mistreatment of African-Americans in 
the pursuit of medical science.
Skloot recounts the infamous 
Tuskegee syphilis study, in which 
poor and uneducated black men 
with the disease were recruited and 
then allowed to die preventable 
deaths while doctors lied to them 
and withheld penicillin so they could 
research the course of the disease.
Chairing the judging panel of five, 
former barrister, comedy writer and 
presenter Clive Anderson said: “This 
is an engaging account of the life of 
Henrietta Lacks, who died in Baltimore 
nearly 60 years ago, and the immortal 
life of her cancer cells, which continue 
to replicate in research laboratories 
around the world to this day.”
He said there are several stories 
to be told: “the changing attitudes 
and ethics of the medical profession, 
the economics of healthcare and the 
successes and slip-ups of modern 
scientific methods. In addition, the 
book reveals the human story of 
Henrietta Lacks’ family, who the 
author got to know in the course  
of her extensive research.”
He thought it a “worthy winner of a 
prize designed to honour fine writing 
on a medical theme.”
Matterson added: “It has something 
of everything — a compelling science 
story, an emotional personal story and 
intriguing ethical dilemmas — all woven 
together and written with great style.”
This was the second year of the 
£25,000 Wellcome Trust book prize, 
which is open to both fiction and 
non-fiction on the theme of health and 
medicine. The short list comprised 
two other works of non-fiction and 
three novels, each giving an insight 
into the medical world.
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Immortal: It is estimated 50 million tonnes of HeLa cells, derived from Henrietta Lacks, have been 
used in research since they were first taken. (Picture: Manfred Kage/Science Photo Library.)
Modified vector 
attack on dengue
Genetically modified mosquitoes 
are showing promise in reducing the 
occurrence of a serious disease.  
Nigel Williams reports.
There is long history of using the 
release of laboratory-modified insects 
to reduce the impact of diseases, 
some with considerable effect, and a 
novel modification is showing promise 
in the fight against dengue fever.
Researchers at the Oxford-based 
company Oxitec announced last 
month that a small-scale trial using 
male mosquitoes that had been 
genetically modified to be dependent 
on an antibiotic had cut numbers of 
the insect in the Cayman Islands by  
80 per cent in six months.
The modified mosquitoes mate as 
normal but die quite quickly in the 
absence of access to tetracycline. 
Their offspring inherit the trait and 
perish quickly too.
“By giving them tetracycline in the 
lab, we can keep them alive and breed 
large numbers of them, but when we 
release them into the environment and 
they mate with wild females, all the 
offspring inherit a copy of the gene 
that kills them if they don’t get the 
antidote… so they die,” says Luke 
Alphey, co-founder of Oxitec.
The mosquito is Aedes aegypti, 
which spreads dengue fever when 
females bite humans. Dengue fever 
causes severe flu-like symptoms 
and can be lethal. The World Health 
Organisation estimates there are  
50 million cases of dengue fever a 
year, of which 25,000 are fatal. About 
2.5 billion people are at risk, mostly in 
Africa and south-east Asia. There is  
no vaccine or treatment and experts 
say new ways of controlling the 
disease are urgently needed  
because of a sharp rise in global 
infection rates over recent years.
Angela Harris of the Mosquito 
Research and Control Unit in the 
Cayman Islands said she was 
encouraged by the trial, conducted 
between April and October this year. 
“This kind of technology really has a 
place for reducing dengue and having 
an impact on human health,” she said.
Alphey said that his company was in 
talks with officials in several countries 
about further and larger trials.
